Clinical Trials Logo

Malignant Neoplastic Disease clinical trials

View clinical trials related to Malignant Neoplastic Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05840510 Recruiting - Metastatic Cancer Clinical Trials

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

Start date: August 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.

NCT ID: NCT05375994 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

RAMP204
Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

NCT ID: NCT04975256 Completed - Metastatic Cancer Clinical Trials

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.

NCT ID: NCT04330664 Active, not recruiting - Metastatic Cancer Clinical Trials

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Start date: April 22, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

NCT ID: NCT03785249 Recruiting - Metastatic Cancer Clinical Trials

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Start date: December 26, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.